teriflunomide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 14 Diseases   33 Trials   33 Trials   2608 News 


«12345678910111213...3132»
  • ||||||||||  teriflunomide / Generic mfg., azacitidine / Generic mfg., gemcitabine / Generic mfg.
    Journal:  Upregulation of cytidine deaminase in NAT1 knockout breast cancer cells. (Pubmed Central) -  Nov 5, 2022   
    The present findings suggest a novel therapeutic strategy to treat breast cancer with elevated NAT1 expression. For instance, NAT1 inhibition may be combined with cytotoxic nucleosides (e.g., 5fdC) for breast cancer treatment.
  • ||||||||||  brequinar (DUP 785) / BMS, Clear Creek Bio
    DHODH: A Promising New Therapeutic Target in Pediatric T-ALL (ENMCC - Hall D) -  Nov 4, 2022 - Abstract #ASH2022ASH_4861;    
    It is known that the intracellular concentration of nucleotides is high in activated T-lymphocytes, underlying the fact that two low-potency DHODHi’s are approved for the treatment of autoimmune T-cell diseases (e.g., teriflunomide for multiple sclerosis and leflunomide for rheumatoid arthritis)...These single agent treatment studies (brequinar, 50 mg/kg given every 3-days) were initiated between day 7 - 14 when the leukemias had engrafted and were established with detectable disease in the bone marrow...New data suggests that changes in mitochondrial membrane potential and mitochondrial mass following exposure to DHODHi may offer additional insights into this sensitivity. We are also studying DHODHi in combination with other approved and experimental agents toward the goal of a new therapeutic combination that is safe, well-tolerated, and efficacious for this patient population.
  • ||||||||||  teriflunomide / Generic mfg.
    Journal, Adverse events, Serious adverse event:  Teriflunomide-induced Raynaud's phenomenon: a serious adverse event, previously unreported. (Pubmed Central) -  Nov 2, 2022   
    We are also studying DHODHi in combination with other approved and experimental agents toward the goal of a new therapeutic combination that is safe, well-tolerated, and efficacious for this patient population. No abstract available
  • ||||||||||  farudodstat (ASLAN003) / Almirall, ASLAN Pharma
    Journal:  Discovery of potent human dihydroorotate dehydrogenase inhibitors based on a benzophenone scaffold. (Pubmed Central) -  Nov 2, 2022   
    Furthermore, 7d exhibited favorable safety profiles in mice and displayed effective antitumor activities with tumor growth inhibition (TGI) rates of 58.3% and 42.1% at an oral dosage of 30 mg/kg in Raji and HCT116 cells xenograft models, respectively. Taken together, these findings provide a promising hDHODH inhibitor 7d with potential activities against some tumors.
  • ||||||||||  teriflunomide / Generic mfg.
    Clinical, Journal, HEOR:  Relationship between Patient Preferences, Attitudes to Treatment, Adherence, and Quality of Life in New Users of Teriflunomide. (Pubmed Central) -  Oct 28, 2022   
    After nine months of teriflunomide therapy, both the disability and quality of life remained stable; the relapse rate significantly decreased, 63.3% of patients had a high adherence, and 100% of patients preferred an oral administration. A low adherence was associated with previous DMT experiences and a low self-efficacy for the appropriate medication (i.e., the confidence in one's ability to take medication correctly).
  • ||||||||||  Tysabri (natalizumab) / Biogen, Royalty, Ocrevus (ocrelizumab) / Roche, Biogen, Mayzent (siponimod) / Novartis
    Journal:  Pathogenesis and management of multiple sclerosis revisited. (Pubmed Central) -  Oct 26, 2022   
    Since the advent of DMTs various other oral and injectable agents have been approved. The advances in MS therapeutics and diagnostics have laid the ground for further research and development to enhance the quality of life of afflicted patients.
  • ||||||||||  teriflunomide / Generic mfg.
    Clinical, Observational data, Journal:  The role of teriflunamide in multiple sclerosis patient: an observational study. (Pubmed Central) -  Oct 25, 2022   
    Patients underwent a full cognitive profile assessment using the Brief Repeatable Battery of Neuropsychological Tests and a neuroimaging examination with a 3.0 T working scanner.Our results suggested that treatment with teriflunomide could potentially not only slow down the accumulation of microstructural tissue damage in Grey Matter and With Matter, but also better preserve the cognitive profile, particularly by highlighting the benefits in the memory domain. Thanks to drug therapy, brain volume in our patients has remained constant, leading to improvements in memory, indicating teriflunomide as a neuroprotective potential and further strengthening the evidence of a link between loss of brain volume and cognitive impairment.
  • ||||||||||  Tysabri (natalizumab) / Biogen, Royalty
    Trial completion, Enrollment change, Trial completion date:  MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV (clinicaltrials.gov) -  Oct 20, 2022   
    P4,  N=55, Completed, 
    Thanks to drug therapy, brain volume in our patients has remained constant, leading to improvements in memory, indicating teriflunomide as a neuroprotective potential and further strengthening the evidence of a link between loss of brain volume and cognitive impairment. Active, not recruiting --> Completed | N=41 --> 55 | Trial completion date: Dec 2022 --> Feb 2022
  • ||||||||||  Socioeconomic Influence on DMT Prescribing Strategies (ePoster Area) -  Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_2000;    
    This difference was seen early in the study with all levels of socioeconomic status trending toward similar rates of high efficacy prescribing by the end. The cause for this lower rate of high-efficacy prescribing will require further evaluation; one theory is that patient assistance programs may distort the economics of DMT affordability for this quartile of patients.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono
    Ageing and Multiple Sclerosis, a prospective study (ePoster Area) -  Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1881;    
    Our study characterizes two cohorts of adult PwMS of different ages but similar disease duration. Comparison between them should allow better understanding of the course of the disease and of the real impact of aging on MS.
  • ||||||||||  Assessing treatment response to oral drugs for multiple sclerosis in real world setting: a MAGNIMS study (ePoster Theatre 4) -  Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1854;    
    We retrospectively evaluated data of RRMS patients who started dimethyl fumarate (DMF), fingolimod (FNG) or teriflunomide (TNF) according to the following criteria: treatment-naive or switching from injectable DMTs; at least 1 year treatment duration; brain MRI scan collected at baseline and year 1; at least 3 years of clinical follow-up... In a multicenter study we report that early relapses and MRI activity in the first year of treatment with oral DMT are associated with an increased risk of short-term confirmed disability worsening and treatment failure in patients treated with oral DMTs.
  • ||||||||||  Utuxin (ublituximab) / TG Therap
    NEDA-4 with ublituximab versus teriflunomide in the ULTIMATE I and II studies in participants with relapsing multiple sclerosis (ePoster Theatre 4) -  Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1851;    
    Because BVL is predictive of long-term disability progression and cognitive decline, inclusion of BVL in NEDA analyses may provide a more comprehensive evaluation of disease activity and progression and might be predictive of long-term disability. In pooled post hoc analyses across a range of annual BVL thresholds, significantly more participants achieved NEDA-4 with ublituximab versus teriflunomide in ULTIMATE I and II.
  • ||||||||||  Ponvory (ponesimod) / J&J
    Preservation of Myelin in Patients with Relapsing Multiple Sclerosis Treated with Ponesimod Compared to Teriflunomide (ePoster Area) -  Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1800;    
    In pooled post hoc analyses across a range of annual BVL thresholds, significantly more participants achieved NEDA-4 with ublituximab versus teriflunomide in ULTIMATE I and II. Ponesimod patients showed either preservation of myelination or less demyelination compared to teriflunomide treated patients, indicating protection of myelin and tissue microstructure.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono
    Real world experience with cladribine treatment in Slovakia (ePoster Area) -  Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1758;    
    Our study confirmed high long-term efficacy of cladribine in MS patients. Considering relative risk of cancer we strictly require patients to have a periodic preventive medical evaluation
  • ||||||||||  Mavenclad (cladribine) / EMD Serono
    Assessment of treatment satisfaction across oral DMTs for multiple sclerosis: A preliminary baseline analysis from the STATURE study (ePoster Area) -  Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1748;    
    Understanding perceived satisfaction related to DMTs prescribed for people with MS is important. While results of this preliminary analysis require cautious interpretation because of the small sample sizes for fingolimod and teriflunomide, identification of baseline differences in medication satisfaction highlights the need for this current research that assesses the relationship between treatment burden, such as administration schedule and side-effects, with medication adherence and quality of life across oral DMT options for people with MS.
  • ||||||||||  Tysabri (natalizumab) / Biogen, Royalty, Ocrevus (ocrelizumab) / Roche, Biogen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Serum GFAP and long-term outcomes in high efficacy versus low efficacy early treatment in multiple sclerosis (ePoster Area) -  Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1747;    
    sNfL and sGFAP tended to decrease over time in HEET and LEET groups. Serum GFAP level during the first few months of treatment initiation was associated with disease progression and time to new T2 lesion in our HEET cohort.
  • ||||||||||  Tysabri (natalizumab) / Biogen, Royalty
    Heterogeneous Virtual Multiple Sclerosis Patients for analysis of personalized treatment responses (ePoster Area) -  Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1724;    
    MS TreatSim generates VPs with heterogeneous immune initializations and treatment responses. Analysis of these VPs in terms of not only efficacy, but also leukocyte number-based safety profiles, can help to characterize the optimal efficacy-safety profile for a patient, as well as which patients are the optimal targets for a treatment.
  • ||||||||||  teriflunomide / Generic mfg.
    COGNITIVE IMPAIRMENT IN EARLY MULTIPLE SCLEROSIS (ePoster Area) -  Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1463;    
    Naive patients with RRMS starting on teriflunomide were selected... Cognitive impairment is present even in the early stages of MS, affecting especially verbal memory, processing speed, attention, and executive function.
  • ||||||||||  Assessing treatment response to oral drugs for Multiple Sclerosis in real world setting: a MAGNIMS study (ePoster Area) -  Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1326;    
    We retrospectively evaluated data of RRMS patients who started dimethyl fumarate (DMF), fingolimod (FNG) or teriflunomide (TNF) according to the following criteria: treatment-naive or switching from injectable DMTs; at least 1 year treatment duration; brain MRI scan collected at baseline and year 1; at least 3 years of clinical follow-up... In a multicenter study we report that early relapses and MRI activity in the first year of treatment with oral DMT are associated with an increased risk of short-term confirmed disability worsening and treatment failure in patients treated with oral DMTs.
  • ||||||||||  Ponvory (ponesimod) / J&J
    Longitudinal clinical and MRI outcomes in Relapsing Multiple Sclerosis patients after short-term ponesimod treatment interruption and re-initiation (ePoster Area) -  Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1267;    
    Patients who completed 108 weeks of ponesimod or teriflunomide treatment in the Phase 3 OPTIMUM study and underwentan accelerated elimination procedurewere eligible to enroll intheopen-label extension(OLE)study, where they receivedponesimod 20 mg. In this study, based on clinical and imaging outcomes, disease activity at OLE 48 weeks following short-term interruption and re-initiation of ponesimod treatment remained consistent with disease activity observed prior to interruption.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
    Earlier Ofatumumab Treatment may Reduce Disease Progression and Relapses for Patients with Relapsing-Remitting Multiple Sclerosis: Results from a Cost-Consequence Model (ePoster Area) -  Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1102;    
    Introduction: Oral disease-modifying therapies (DMTs), such as dimethyl fumarate (DMF), are the most common treatments prescribed for relapsing-remitting multiple sclerosis (RRMS) in the NHS; infusion DMTs are less frequently used.[1] Ofatumumab, a self-administered subcutaneous MS DMT, is effective at reducing relapses and slowing disease progression compared with teriflunomide, as demonstrated in the ASCLEPIOS trials.[2] During the NICE appraisal, clinical experts noted that ofatumumab could be used as a first-line treatment for RRMS... Over 10 years, ofatumumab treatment was predicted to reduce relapse events and result in fewer patients progressing to EDSS ≥7 when compared with those receiving delayed ofatumumab (after 3 years of DMF), or DMF only.
  • ||||||||||  Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech
    Effective humoral and cellular immunity in mRNA-COVID-19 multiple sclerosis vaccinees treated with Teriflunomide (ePoster Area) -  Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1098;    
    P=N/A
    We prospectively measured (1) SARS-COV-2 IgG response using a quantitative anti-spike protein-based immunoassay (Euroimmun, Lubeck, Germany, cut-off IgG level >35.2 BAU/ml), (2) memory B-cells specific for SARS-CoV-2 RBD, and (3) memory T-cells secreting IFN-g and/or IL-2, in response to SARS-CoV-2 peptides by ELISpot/Fluorospot assays, in MS patients vaccinated with BNT162b2-COVID-19 vaccine before, one and three months after the second vaccine dose. Teriflunomide treatment enabled effective humoral and cellular immune responses to COVID-19 vaccination.
  • ||||||||||  glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
    Single-dose immunisation with live attenuated vaccines is an effective option before treatment initiation in MS patients (ePoster Area) -  Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1094;    
    A single dose-attempt of VVZ and/or MMR following confirmation by post-vaccination serology could be sufficient to provide protection in almost two thirds of patients. It could be included in the routine clinical practice to achieve a rapid immunisation, especially in highly active patients who need immunosuppressive therapy.